NCT04536077View on ClinicalTrials.gov

Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 13, 2021

Primary Completion Date

November 21, 2023

Study Completion Date

November 21, 2023

Conditions
Pancreatic CancerCancer of the PancreasPancreas Cancer
Interventions
DRUG

CDX-301

The drug will be supplied free of charge by Celldex

DRUG

CDX-1140

The drug will be supplied free of charge by Celldex

PROCEDURE

Research blood draw

At screening; prior to first therapeutic dose of CDX-1140, on the day of the infusion; and at the time of surgery

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Celldex Therapeutics
All Listed Sponsors
collaborator

Celldex Therapeutics

INDUSTRY

collaborator

The Foundation for Barnes-Jewish Hospital

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

Washington University School of Medicine

OTHER

NCT04536077 - Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients | Biotech Hunter | Biotech Hunter